tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Hallucinations D006212 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Prurigo D011536 4 associated lipids
Meningoencephalitis D008590 4 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Viremia D014766 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Gout D006073 4 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Ovarian Cysts D010048 4 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Confusion D003221 4 associated lipids
Parotitis D010309 4 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Bone Diseases D001847 4 associated lipids
Foot Ulcer D016523 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Eczema D004485 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Neuritis D009443 4 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Pain, Intractable D010148 4 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Headache D006261 4 associated lipids
Diabetes Complications D048909 4 associated lipids
Balanitis D001446 4 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Amenorrhea D000568 4 associated lipids
Blepharitis D001762 4 associated lipids
Legionellosis D007876 3 associated lipids
Pityriasis D010915 3 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Perceptual Disorders D010468 3 associated lipids
Hematologic Diseases D006402 3 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Lichen Planus D008010 3 associated lipids
Toxocariasis D014120 3 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Meningococcal Infections D008589 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Trichomonas Infections D014245 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Impetigo D007169 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Paronychia D010304 3 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Gingivitis D005891 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Facial Neoplasms D005153 3 associated lipids
Pouchitis D019449 3 associated lipids
Cryptococcosis D003453 3 associated lipids
Hemophilia B D002836 3 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Pemphigus D010392 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Pterygium D011625 3 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Intestinal Atresia D007409 3 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Hyperkalemia D006947 3 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Immune System Diseases D007154 3 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Castleman Disease D005871 3 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Anus Diseases D001004 3 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Scleritis D015423 3 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Ileus D045823 3 associated lipids
Anemia, Refractory D000753 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hossain MA et al. Immunosuppression in auxiliary partial liver transplantation with FK506 in rats. 1997 Transplant. Proc. pmid:9414861
Miyata Y et al. Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of FKBP52. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9405642
Zucker K et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. 1997 Transpl. Immunol. pmid:9402690
Suzuki J et al. Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation. 1997 J. Heart Lung Transplant. pmid:9402514
Misao T et al. Efficacy of combining donor-specific presensitization with a simultaneous single injection of tacrolimus on pulmonary allografts. 1997 J. Heart Lung Transplant. pmid:9402508
Wijnen RM and Ericzon BG Update of tacrolimus in pancreas transplantation. 1997 Diabet. Med. pmid:9400914
Mollison KW et al. Discovery of less nephrotoxic FK506 analogs and determining immunophilin dependence of immunosuppressant nephrotoxicity with a novel single-dose rat cisplatin potentiation assay. 1997 J. Pharmacol. Exp. Ther. pmid:9400028
Cox TH et al. Bradycardia associated with intravenous administration of tacrolimus in a liver transplant recipient. 1997 Nov-Dec Pharmacotherapy pmid:9399620
Yamaguchi Y et al. Enhanced expression of cytokine-induced neutrophil chemoattractant in rat hepatic allografts during acute rejection. 1997 Hepatology pmid:9397996
Su Y et al. Thyroid hormone induces apoptosis in primary cell cultures of tadpole intestine: cell type specificity and effects of extracellular matrix. 1997 J. Cell Biol. pmid:9396758
Sabatini DM et al. Neural roles of immunophilins and their ligands. 1997 Mol. Neurobiol. pmid:9396011
Schweda F et al. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. 1997 Nephrol. Dial. Transplant. pmid:9394341
Jiang H et al. Distinct tissue and cellular distribution of two major isoforms of calcineurin. 1997 Mol. Immunol. pmid:9393969
Sokal EM et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. 1997 Transplantation pmid:9392308
Kageyama S et al. Augmentation of natural killer cell activity induced by cytomegalovirus infection in mice treated with FK506. 1997 Acta Virol. pmid:9391652
Nyanguile O et al. A nonnatural transcriptional coactivator. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9391036
Huang J and Schreiber SL A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9391035
McElwee KJ et al. Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. 1997 Br. J. Dermatol. pmid:9390322
Thyagarajan GK et al. FK506-induced fulminant leukoencephalopathy after single-lung transplantation. 1997 Ann. Thorac. Surg. pmid:9386723
Okudaira H et al. Control of allergic diseases by regulation of cytokine gene transcription. 1997 Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M pmid:9383912
Chakraborty TK et al. Design and synthesis of a rapamycin-based high affinity binding FKBP12 ligand. 1995 Chem. Biol. pmid:9383417
Pruschy MN et al. Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012. 1994 Chem. Biol. pmid:9383386
Newell KA et al. Treatment with either anti-CD4 or anti-CD8 monoclonal antibodies blocks alphabeta T cell-mediated rejection of intestinal allografts in mice. 1997 Transplantation pmid:9381541
De Gasperi A and Rohrer RJ Scenario number two: sepsis and multiorgan failure after liver transplantation. 1997 Liver Transpl Surg pmid:9377761
Canzanello VJ et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). 1997 Liver Transpl Surg pmid:9377752
Kuromitsu S et al. 3-(13-Hydroxytridecyl)-1-[13-(3-pyridyl)tridecyl]pyridinium chloride (YM-53792), a novel inhibitor of NF-AT activation. 1997 Biochem. Pharmacol. pmid:9374420
Cetinkale O et al. Involvement of neutrophils in ischemic injury. I. Biochemical and histopathological investigation of the effect of FK506 on dorsal skin flaps in rats. 1997 Ann Plast Surg pmid:9374148
Rudant E et al. Study of the correlation between MEIA and ELISA methods for FK 506 determination in liver transplant recipients. 1997 J Clin Pharm Ther pmid:9373812
Eberlein-König B et al. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. 1997 Arch. Dermatol. Res. pmid:9373722
Kloke O et al. Rapamycin antagonizes interleukin-6 mediated growth arrest and differentiation of myeloblastic M1 cells. 1997 Immunol. Lett. pmid:9373220
Migita K et al. FK506 potentiates steroid-induced T-cell apoptosis. 1997 Transplantation pmid:9371682
Lee CM et al. Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. 1997 Transplantation pmid:9371670
Ross DJ et al. FK 506 'rescue' immunosuppression for obliterative bronchiolitis after lung transplantation. 1997 Chest pmid:9367453
Aoyama S et al. [The effect of FK 506, an immunosuppressant, on cerebral infarction volume in focal cerebral ischemia in rats]. 1997 Nippon Ika Daigaku Zasshi pmid:9366145
Takao T et al. [A case of recurrent IgA nephropathy following renal transplantation under tacrolimus (FK506)]. 1997 Hinyokika Kiyo pmid:9365847
Niederstadt C et al. Effect of FK506 on magnesium homeostasis after renal transplantation. 1997 Transplant. Proc. pmid:9365709
Gavlik A et al. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. 1997 Transplant. Proc. pmid:9365633
Xu M et al. Effect of peritransplant FTY720 alone or in combination with posttransplant FK 506 in a rat model of cardiac allotransplantation. 1997 Transplant. Proc. pmid:9365631
Kliem V et al. Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients. 1997 Transplant. Proc. pmid:9365627
Demirbas A et al. FK 506 in simultaneous pancreas/kidney transplantation: the University of Miami experience. 1997 Transplant. Proc. pmid:9365608
Platz KP et al. Indications for mycofenolate mofetil therapy after liver transplantation. 1997 Transplant. Proc. pmid:9365601
Platz KP et al. FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. 1997 Transplant. Proc. pmid:9365598
Mueller AR et al. Association between hepatitis and rejection: upregulation of cytokines and extracellular matrix parameters. 1997 Transplant. Proc. pmid:9365585
Taylor PJ et al. Improved therapeutic drug monitoring of tacrolimus (FK506) by tandem mass spectrometry. 1997 Clin. Chem. pmid:9365410
Dumont FJ FK506 enhances IL-13 production by T cells activated through CD3/CD28. 1997 Int. Arch. Allergy Immunol. pmid:9363914
Xenos EX et al. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60. 1997 Clin Transplant pmid:9361949
Neu AM et al. Evaluation of neurotoxicity in pediatric renal transplant recipients treated with tacrolimus (FK506). 1997 Clin Transplant pmid:9361932
Reyes J et al. Graft-versus-host disease after liver and small bowel transplantation in a child. 1997 Clin Transplant pmid:9361921
Nakai A et al. The immunosuppressant drug FK506 ameliorates secondary mitochondrial dysfunction following transient focal cerebral ischemia in the rat. 1997 Neurobiol. Dis. pmid:9361306
Rinaldi M et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. 1997 J. Heart Lung Transplant. pmid:9361242